News
RGNX
8.63
+2.98%
0.25
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
PR Newswire · 21h ago
Weekly Report: what happened at RGNX last week (0323-0327)?
Weekly Report · 3d ago
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
PR Newswire · 3d ago
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire · 3d ago
Regenxbio shares drop 17.8% due to RGX-111 securities class action; lead plaintiff deadline set for April 14, 2026
Reuters · 6d ago
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
PR Newswire · 6d ago
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
Benzinga · 6d ago
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
PR Newswire · 03/24 22:36
Shareholders Sue RGNX Over Gene Therapy Study Claims
TipRanks · 03/24 15:47
Bank of America Securities Keeps Their Buy Rating on RegenXBio (RGNX)
TipRanks · 03/24 10:17
Weekly Report: what happened at RGNX last week (0316-0320)?
Weekly Report · 03/23 09:38
Regenxbio Enters Settlement And Release Agreement With GlaxoSmithKline On March 18, 2026; To Pay $10.0M To GlaxoSmithKline For Alleged Underpayment Of Sublicense Fees; Settlement Agreement Includes Mutual Releases Of Past And Certain Future Claims; To Continue To Pay GSK Amounts Received From Sublicensees Pursuant To Existing Sublicense Agreements
Benzinga · 03/20 21:34
RegenXBio Reaches Settlement with GSK Over License Fees
TipRanks · 03/20 21:28
REGENXBIO INC - TO CONTINUE TO PAY GSK AMOUNTS RECEIVED FROM SUBLICENSEES PURSUANT TO EXISTING SUBLICENSE AGREEMENTS - SEC FILING
Reuters · 03/20 21:17
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
NASDAQ · 03/20 12:00
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
NASDAQ · 03/20 11:59
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
NASDAQ · 03/20 11:59
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
PR Newswire · 03/20 00:05
Class Action Lawsuit Targets Regenxbio Over RGX-111 Statements
Reuters · 03/19 16:01
More
Webull provides a variety of real-time RGNX stock news. You can receive the latest news about Regenxbio through multiple platforms. This information may help you make smarter investment decisions.
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.